source
- Roche remains bullish on giredestrant despite first-line trial setbackRoche's CEO Thomas Schinecker said the company still expects its investigational oral breast cancer therapy giredestrant to generate strong sales, potentially surpassing Herceptin. The optimism fo…
- Trump touts completion of first round of White House drug pricing deals with RegeneronPresident Trump announced that a pricing agreement with Regeneron marks the final deal of an initial slate of 17 sought by the administration. Under the private arrangement, Regeneron will lower Me…